Y
Yi Liu
Researcher at Fourth Military Medical University
Publications - 43
Citations - 1773
Yi Liu is an academic researcher from Fourth Military Medical University. The author has contributed to research in topics: Reperfusion injury & Medicine. The author has an hindex of 18, co-authored 35 publications receiving 1264 citations.
Papers
More filters
Journal ArticleDOI
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.
Chao Gao,Yue Cai,Kan Zhang,Lei Zhou,Yao Zhang,Xijing Zhang,Qi Li,Weiqin Li,Shiming Yang,Xiaoyan Zhao,Yuying Zhao,Hui Wang,Yi Liu,Zhiyong Yin,Ruining Zhang,Rutao Wang,Ming Yang,Chen Hui,William Wijns,J William McEvoy,Osama Ibrahim Ibrahim Soliman,Yoshinobu Onuma,Patrick W. Serruys,Patrick W. Serruys,Ling Tao,Fei Li +25 more
TL;DR: While hypertension and the discontinuation of antihypertensive treatment are suspected to be related to increased risk of mortality, in this retrospective observational analysis, it did not detect any harm of RAAS inhibitors in patients infected with COVID-19.
Journal ArticleDOI
TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury.
Yi Liu,Kun Lian,Lijian Zhang,Rutao Wang,Fu Yi,Chao Gao,Chao Xin,Di Zhu,Yan Li,Wenjun Yan,Lize Xiong,Erhe Gao,Haichang Wang,Ling Tao +13 more
TL;DR: For the first time, TXNIP-mediated NLRP3 inflammasome activation in CMECs was a novel mechanism of MI/R injury and interventions that block Txnip/NLRP3 signaling to inhibit the activation of NLRP2 inflammaome may be novel therapies for mitigating MI/ R injury.
Journal ArticleDOI
Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway
Chao Xin,Jingyi Liu,Jinglong Zhang,Di Zhu,Huaning Wang,Lize Xiong,Yan Lee,J Ye,Kun Lian,C Xu,Ling Zhang,Q Wang,Yi Liu,Ling Tao +13 more
TL;DR: It is suggested that irisin has an essential role in glucose utilization and lipid metabolism, and irisin is a promising pharmacological target for the treatment of diabetes and its complications.
Journal ArticleDOI
Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses.
Di Zhu,Haichang Wang,Jinglong Zhang,Xiaotian Zhang,Chao Xin,Fuyang Zhang,Yan Lee,Ling Zhang,Kun Lian,Wenjun Yan,Xin-Liang Ma,Yi Liu,Ling Tao +12 more
TL;DR: In this article, the authors investigated whether irisin improved endothelial function in type 2 diabetes as well as the underlying mechanisms, and they found that irisin treatment (0.5 mg/kg/d) for two weeks improved vascular function based on the evaluation of endothelium-dependent vasorelaxation and p-VASP levels.
Journal ArticleDOI
Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1α signaling contributing to increased vulnerability in diabetic heart.
Wenjun Yan,Haifeng Zhang,Peilin Liu,Han Wang,Jingyi Liu,Chao Gao,Yi Liu,Kun Lian,Lu Yang,Lu Sun,Yunping Guo,Lijian Zhang,Ling Dong,Wayne Bond Lau,Erhe Gao,Feng Gao,Lize Xiong,Haichang Wang,Yan Qu,Ling Tao +19 more
TL;DR: In this article, an electron microscopy revealed significant mitochondrial disorders in ob/ob cardiomyocytes, including mitochondrial swelling and cristae disorientation and breakage, as well as reduced Ppargc-1a/Nrf-1/Tfam mRNA levels.